Odyssey Therapeutics, Inc. (ODTX)
NASDAQ: ODTX · Real-Time Price · USD
21.18
+0.83 (4.08%)
Aug 12, 2026, 12:51 PM EDT - Market open
Odyssey Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 82.03 | 41.69 | 59.14 | 52.55 | 241.04 |
Short-Term Investments | 228.54 | 139.67 | 70.22 | 134.45 | - |
Cash & Short-Term Investments | 310.58 | 181.36 | 129.35 | 187 | 241.04 |
Cash Growth | 140.10% | 40.20% | -30.83% | -22.42% | - |
Other Current Assets | 10.89 | 9.3 | 6.16 | 5.54 | 7.67 |
Total Current Assets | 321.46 | 190.66 | 135.51 | 192.54 | 248.71 |
Net Property, Plant & Equipment | 21.92 | 26.01 | 39.47 | 46.73 | 52.77 |
Other Intangible Assets | 0.09 | 0.26 | 0.57 | 0.91 | 1.18 |
Goodwill | 14.1 | 14.33 | 13.35 | 13.55 | 12.88 |
Long-Term Investments | 122.49 | 35.2 | - | 29.1 | - |
Other Long-Term Assets | 3.79 | 3.33 | 8.54 | 3.69 | 1.61 |
Total Assets | 483.85 | 269.79 | 197.44 | 286.52 | 317.15 |
Accounts Payable | 7.67 | 7.87 | 6.32 | 7.73 | 8.05 |
Accrued Expenses | 15.16 | 13.39 | 17.52 | 10.5 | 11.39 |
Current Portion of Leases | 5.47 | 5.21 | 4.58 | 3.86 | 1.72 |
Other Current Liabilities | - | - | - | - | 1.63 |
Total Current Liabilities | 28.3 | 26.48 | 28.42 | 22.09 | 22.8 |
Long-Term Debt | - | - | - | - | 4.76 |
Long-Term Leases | 19.36 | 21.9 | 26.43 | 30.52 | 34.38 |
Other Long-Term Liabilities | 14.97 | 6.13 | 10.22 | 8.41 | 8.2 |
Total Long-Term Liabilities | 34.33 | 28.03 | 36.65 | 38.94 | 47.34 |
Total Liabilities | 62.63 | 54.51 | 65.07 | 61.02 | 70.14 |
Common Stock | 0.01 | - | - | 0 | 0 |
Additional Paid-in Capital | 1,081 | 79.62 | 38.31 | 27.24 | 15.73 |
Accumulated Other Comprehensive Income | -0.51 | 0.25 | -1.34 | -0.86 | -2.18 |
Retained Earnings | -659.19 | -568.14 | -419.49 | -289.09 | -158.17 |
Total Common Shareholders' Equity | 421.22 | -488.28 | -382.53 | -262.71 | -144.62 |
Minority Interest | - | 703.56 | 514.89 | 488.21 | 391.63 |
Shareholders' Equity | 421.22 | 215.28 | 132.37 | 225.5 | 247.01 |
Total Liabilities & Equity | 483.85 | 269.79 | 197.44 | 286.52 | 317.15 |
Total Debt | 24.83 | 27.11 | 31.01 | 34.38 | 40.86 |
Net Cash (Debt) | 285.75 | 154.25 | 98.35 | 152.62 | 200.18 |
Net Cash Growth | 190.55% | 56.84% | -35.56% | -23.76% | - |
Net Cash Per Share | 25.00 | 50.77 | 111.78 | 235.52 | 447.04 |
Book Value | 421.22 | -488.28 | -382.53 | -262.71 | -144.62 |
Book Value Per Share | 36.86 | -160.72 | -434.77 | -405.41 | -322.96 |
Tangible Book Value | 407.04 | -502.87 | -396.44 | -277.17 | -158.68 |
Tangible Book Value Per Share | 35.62 | -165.52 | -450.59 | -427.74 | -354.35 |